The Weekly Dose: New Executive Order, Teplizumab Approval, and Conference Roundup

In this episode of The Weekly Dose, hosts Danielle Valletti, assistant editor, and Kennedy Ferruggia, associate editor at Pharmacy Times, break down 4 major stories shaping pharmacy practice.

An executive order signed by President Donald J. Trump on April 18, 2026, directs federal agencies to accelerate the development and potential approval of psychedelic-based therapies for conditions such as posttraumatic stress disorder (PTSD), depression, and substance use disorders.

Michael Ganio, PharmD, MS, BCPS, FASHP, senior director of pharmacy practice and quality at the American Society of Health-System Pharmacists, spoke with Pharmacy Times about how global conflicts and trade disruptions could affect the US drug supply chain, particularly for older generic medications sourced overseas.

The FDA has approved a supplemental biologic license application for teplizumab-mzwv (Tzield; Sanofi).

The FDA has also expanded the approval for dupilumab (Dupixent; Sanofi/ Regeneron Pharmaceuticals) for the treatment of children aged 2 to 11 years with chronic spontaneous urticaria.

Pharmacy Times was on site at the American Academy of Neurology Annual Meeting, April 18 to 22, in Chicago.

Pharmacy Times will be on site at the Community Oncology Alliance conference, April 28 to 29, in Orlando. You can find that coverage here.